Agilent Technologies (NYSE:A) Rating Reiterated by Stifel Nicolaus

Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reissued by analysts at Stifel Nicolaus in a research report issued to clients and investors on Monday, Stock Target Advisor reports. They presently have a $151.00 target price on the medical research company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 7.21% from the stock’s current price.

A has been the subject of several other reports. Bank of America upped their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday. Robert W. Baird decreased their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research report on Thursday, May 30th. Barclays lifted their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Friday. TD Cowen increased their price target on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Evercore ISI increased their target price on Agilent Technologies from $130.00 to $135.00 and gave the stock an “in-line” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $140.80.

Agilent Technologies Stock Down 0.0 %

NYSE A traded down $0.03 during trading on Monday, reaching $140.84. 352,227 shares of the company’s stock were exchanged, compared to its average volume of 1,749,380. The company has a 50 day moving average price of $134.16 and a two-hundred day moving average price of $138.60. The stock has a market cap of $41.09 billion, a P/E ratio of 33.30, a price-to-earnings-growth ratio of 4.86 and a beta of 1.05. Agilent Technologies has a 1 year low of $96.80 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The business’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.43 EPS. On average, equities research analysts anticipate that Agilent Technologies will post 5.24 EPS for the current fiscal year.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the sale, the senior vice president now owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders sold 20,874 shares of company stock worth $2,811,770 over the last ninety days. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in shares of Agilent Technologies during the first quarter worth $938,000. Cetera Investment Advisers increased its holdings in Agilent Technologies by 953.3% during the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after purchasing an additional 29,590 shares in the last quarter. UBS Group AG raised its stake in shares of Agilent Technologies by 84.5% in the 4th quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock valued at $45,281,000 after purchasing an additional 149,159 shares during the period. TD Asset Management Inc lifted its holdings in shares of Agilent Technologies by 27.1% in the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after purchasing an additional 343,175 shares in the last quarter. Finally, iA Global Asset Management Inc. boosted its position in shares of Agilent Technologies by 26.2% during the first quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after buying an additional 4,523 shares during the period. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.